Amphotericin B a) Amphotericin B (conventional)- Injection 50 mg

🧪 Amphotericin B (Conventional) – Injection 50 mg

Amphotericin B (conventional) is a yellow to orange lyophilized powder that requires reconstitution before intravenous use.
It is a polyene antifungal agent, primarily used in serious systemic fungal infections.
The injection contains Amphotericin B with deoxycholate, making it the conventional form.
After reconstitution, it forms a colloidal suspension, administered slowly via IV infusion.
Each vial typically contains 50 mg of Amphotericin B, with buffers and stabilizers.

Polyene macrolide antifungal derived from Streptomyces nodosus.
Exhibits fungicidal or fungistatic action, depending on the organism and drug concentration.
Acts by binding to ergosterol in fungal cell membranes, forming pores that cause cell leakage and death.
Poorly absorbed orally – hence always given parenterally for systemic action.
It has a broad antifungal spectrum, especially against Candida, Aspergillus, Cryptococcus, and Histoplasma.

Gold standard for treating life-threatening fungal infections.
Effective in immunocompromised patients, including those with HIV/AIDS, cancer, and transplant recipients.
Does not significantly cause fungal resistance, unlike some newer agents.
Can penetrate most tissues, including the central nervous system (CNS) in high doses.
Widely studied and has decades of clinical experience and guidelines for use.

Systemic fungal infections such as candidiasis, aspergillosis, and cryptococcosis.
Treatment of mucormycosis, especially in diabetic or post-COVID patients.
Used in visceral leishmaniasis (kala-azar) in endemic areas.
Indicated for fungal meningitis and disseminated mycoses.
May be used empirically in neutropenic patients with persistent fevers.

Store the unreconstituted vial at 2–8°C (refrigerated); protect from light.
After reconstitution, the solution must be used within 24 hours if stored refrigerated.
Do not freeze the reconstituted solution.
Handle under aseptic conditions during preparation to avoid contamination.
Ensure slow IV infusion over 2–6 hours to minimize nephrotoxicity and infusion-related reactions.